Chiron, Roche Settle HCV/HIV Patent Dispute Via $115 Mil. Licensing Pact
This article was originally published in The Gray Sheet
Executive Summary
A licensing agreement struck between Chiron and Roche, announced Oct. 11, resolves patent litigation pending against Roche in the U.S. and overseas related to probe-based hepatitis C virus (HCV) and HIV clinical diagnostics while leaving intact complaints against Roche in Germany related to antibody-based HCV immunoassay diagnostic patents.